Details for Patent: 12,023,312
✉ Email this page to a colleague
Which drugs does patent 12,023,312 protect, and when does it expire?
Patent 12,023,312 protects SOHONOS and is included in one NDA.
This patent has thirty-one patent family members in nineteen countries.
Summary for Patent: 12,023,312
| Title: | Composition and method for muscle repair and regeneration |
| Abstract: | The invention provides methods for muscle repair or regeneration comprising administering therapeutically effective amounts of RAR agonists or stem cells that are pretreated with contact with a RAR agonist to a subject at a site of muscle damage. Additionally, the invention provides compositions comprising RAR agonist treated stem cells and methods of use of said cells for muscle repair or regeneration. In one embodiment, the stem cells are mesenchymal stem cells. In one embodiment, the RAR agonist is an RARγ agonist. In one embodiment, administration of the RAR agonist is begun during a period of increased endogenous retinoid signaling in the subject resulting from incurrence of the damaged muscle tissue. |
| Inventor(s): | Masahiro Iwamoto, Maurizio Pacifici |
| Assignee: | Thomas Jefferson University |
| Application Number: | US17/881,207 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 12,023,312 |
|
Patent Claim Types: see list of patent claims | |
| Patent landscape, scope, and claims: |
More… ↓ |
Recent additions to Drugs Protected by US Patent 12,023,312
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist Req. | Patent Expiration | Usecode | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ipsen | SOHONOS | palovarotene | CAPSULE | 215559 | Aug 16, 2023 | RX | Yes | ⤷ Start Trial | ⤷ Start Trial | U-3966 | REDUCTION OF HETEROTOPIC OSSIFICATION IN PATIENTS WITH FIBRODYSPLASIA OSSIFICANS (MYOSITIS) PROGRESSIVA | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Type | >RLD | >Patent No. | >Product | >Substance | >Delist Req. | >Patent Expiration | >Usecode | >Patented / Exclusive Use |
Drugs Protected by US Patent 12,023,312
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ipsen | SOHONOS | palovarotene | CAPSULE;ORAL | 215559-001 | Aug 16, 2023 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | REDUCTION OF HETEROTOPIC OSSIFICATION IN PATIENTS WITH FIBRODYSPLASIA OSSIFICANS (MYOSITIS) PROGRESSIVA | ⤷ Start Trial | ||||
| Ipsen | SOHONOS | palovarotene | CAPSULE;ORAL | 215559-002 | Aug 16, 2023 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | REDUCTION OF HETEROTOPIC OSSIFICATION IN PATIENTS WITH FIBRODYSPLASIA OSSIFICANS (MYOSITIS) PROGRESSIVA | ⤷ Start Trial | ||||
| Ipsen | SOHONOS | palovarotene | CAPSULE;ORAL | 215559-003 | Aug 16, 2023 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | REDUCTION OF HETEROTOPIC OSSIFICATION IN PATIENTS WITH FIBRODYSPLASIA OSSIFICANS (MYOSITIS) PROGRESSIVA | ⤷ Start Trial | ||||
| Ipsen | SOHONOS | palovarotene | CAPSULE;ORAL | 215559-004 | Aug 16, 2023 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | REDUCTION OF HETEROTOPIC OSSIFICATION IN PATIENTS WITH FIBRODYSPLASIA OSSIFICANS (MYOSITIS) PROGRESSIVA | ⤷ Start Trial | ||||
| Ipsen | SOHONOS | palovarotene | CAPSULE;ORAL | 215559-005 | Aug 16, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | REDUCTION OF HETEROTOPIC OSSIFICATION IN PATIENTS WITH FIBRODYSPLASIA OSSIFICANS (MYOSITIS) PROGRESSIVA | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,023,312
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2011296080 | ⤷ Start Trial | |||
| Brazil | 112013004685 | ⤷ Start Trial | |||
| Canada | 2809374 | ⤷ Start Trial | |||
| Chile | 2013000580 | ⤷ Start Trial | |||
| China | 103200937 | ⤷ Start Trial | |||
| China | 111773213 | ⤷ Start Trial | |||
| Colombia | 6680694 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
